Pathobiotek Reports Receipt of 'Notice of Allowability' for the Patent on The Intellectual Property of the Viral Project
June 16, 2000 11:02 AM Eastern Time
HOUSTON, June 16 /PRNewswire/ -- Pathobiotek Diagnostics Inc. PBTK (http://www.pathobiotek.com), a developer of products for the diagnosis and evaluation of treatment for multiple sclerosis (MS) and other immune disorders, announced the receipt of the "Certificate of Allowability" for the patent. The actual issuance of the patent is now a formality, which will occur within a few days after the paperwork is returned to the patent office.
The company's investigations have demonstrated that the Activating Virus (AV) is a novel virus found in humans with a variety of cancers and immunosuppressive diseases plus marmosets with wasting syndrome. Wasting syndrome in marmosets resembles AIDS in humans. AV is associated with cancerous cell lines and may be a cofactor in human tumors. Studies to further characterize the genetic composition of this virus are ongoing.
The commercial value of this patent has enormous upside potential and could be of significant financial benefit to Pathobiotek.
Additional information on Pathobiotek Diagnostics Inc. can be obtained at pathobiotek.com.
Safe Harbor for Forward-Looking Statements: Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the company's actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, risk inherent in the company's domestic and international operations, imprecision in estimating product reserves and the company's ability to replace and expand its holdings.
More Quotes and News: Pathobiotek Diagnostics Inc. PBTK . Related News Categories: biotech, medical/pharmaceutical .
SOURCE Pathobiotek Diagnostics Inc.
|
